Withdrawn Study Planned to Assess IDegLira for Type 2 Diabetes Blood Sugar Control
Background
Many individuals with Type 2 Diabetes (T2D) struggle to achieve optimal blood sugar control, even when treated with insulin. Specifically, patients on premix insulin often face challenges with glycaemic variability and may require more advanced therapeutic options. This study was designed to evaluate the real-world effectiveness of IDegLira (insulin degludec/liraglutide) in T2D patients previously treated with premix insulin in Croatia.
Study Design
Results
Due to the study's withdrawal prior to enrollment, no data was collected, and therefore no findings regarding the efficacy or safety of IDegLira in this patient population can be reported. The study's status of 0 actual enrollment means that the intended 36-week observation period for glycaemic control was never initiated. Consequently, there are no results from this specific study to indicate how IDegLira would perform in Type 2 Diabetes patients previously on premix insulin in a real-world Croatian setting.
Why It Matters
While this specific study did not yield data, the initial intent highlights a critical area of need: understanding how combination therapies like IDegLira perform in real-world settings for patients whose Type 2 Diabetes is inadequately controlled by premix insulin. IDegLira combines a long-acting basal insulin (insulin degludec) with a GLP-1 receptor agonist (liraglutide), offering a dual mechanism to improve glycaemic control and potentially reduce weight. Gathering such real-world evidence is crucial for optimizing treatment strategies and informing clinical guidelines for patients transitioning from premix insulin. Future studies addressing this specific patient population remain important for advancing Type 2 Diabetes management.